ArticleIrish veterinary journal2026
In vivo antibacterial activity of chitosan nanoparticles against Clostridium perfringens-induced necrotic enteritis in broilers.
Article in Irish veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNecrotic enteritis (NE) is a major disease affecting broiler productivity, primarily caused by Clostridium perfringens. The extensive use of antibiotics to control NE has led to concerns about antimicrobial resistance and food safety, highlighting the need for safe and effective alternatives. Chitosan nanoparticles (CsNPs) have emerged as promising candidates due to their antibacterial, biodegradable, and nontoxic properties. This study aimed to evaluate the therapeutic potential of CsNPs against C. perfringens infection in broilers by assessing clinical signs, mortality, growth performance, bacterial load, immune response, and histopathological changes. Sixty 1-day-old Ross 308 chicks were randomly divided into four groups (15 birds each): G1 (negative control), G2 (C. perfringens-infected), G3 (infected + CsNPs), and G4 (CsNPs only). Birds in G2 and G3 were orally inoculated with C. perfringens (4×10⁸ CFU/mL) for two consecutive days, while CsNPs (250 µg/bird) were administered to G3 and G4. During the experiment, the birds were assessed for growth performance, intestinal microbial loads, immune organ indexes, and histopathological lesions.
resultsOver the 35-day trial, CsNPs treatment significantly improved body weight (BW), body weight gain (BWG), and feed conversion ratio (FCR) in G3 and G4 compared to G2 (P < 0.05). CsNPs reduced clinical signs and mortality and markedly decreased intestinal colonization by C. perfringens. Immune organ indices (spleen, bursa, and thymus) were significantly enhanced in CsNP-treated birds. Histopathological examination revealed that CsNPs mitigated lesions in the intestine, liver, and lymphoid organs.
conclusionChitosan nanoparticles effectively reduced the severity of necrotic enteritis in broilers, improving growth performance, intestinal health, and immune response. These findings indicate that CsNPs could serve as a safe, natural, and sustainable alternative to antibiotics for controlling C. perfringens infections in poultry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.